COPD Archives -

Respira Labs’ wearable device listens for lung diseases

Phil Taylor asthma, COPD, COVID-19, digital, digital health, patient monitoring, Respira Labs, respiratory, Sylvee 0 Comment

US company Respira Labs has developed a device worn on the chest that uses tiny speakers and microphones

Respira Labs’ wearable device listens for lung diseases

https://pharmaphorum.com/news/respiras-wearable-device-listens-for-lung-diseases/

Digital/ News/ News

Kaia Health raises $75m for digital musculoskeletal disease therapy

Richard Staines COPD, digital, Kaia Health, musculoskeletal disease 0 Comment

Kaia Health has raised a further $75m to expand its AI-based treatment for Musculoskeletal (MSK) and chronic obstructive

Kaia Health raises $75m for digital musculoskeletal disease therapy

https://pharmaphorum.com/news/kaia-health-raises-75m-for-digital-musculoskeletal-disease-therapy/

About pharmaphorum/ Digital/ Views & Analysis/ Views and analysis

Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace

Richard Staines AI, COPD, digital health, Kaia Health, musculoskeletal 0 Comment

Kaia Health has just announced a $75 million funding round for its technology, aimed at improving musculoskeletal (MSK)

Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace

https://pharmaphorum.com/views-and-analysis/kaia-health-gets-75m-for-digital-solution-to-strains-and-pains-of-pandemic-workplace/

Market Access/ News/ News

Hikma shares rally after US launch of Advair generic resumes

Richard Staines Advair, asthma, COPD, respiratory diseases 0 Comment

Shares in Hikma have rallied as it resumed the launch of its generic Advair Diskus in the US,

Hikma shares rally after US launch of Advair generic resumes

https://pharmaphorum.com/news/hikma-shares-rally-after-us-launch-of-advair-generic-resumes/

Market Access/ News/ News

AstraZeneca breathes sigh of relief as court blocks US Symbicort generic

Richard Staines asthma, AstraZeneca, COPD, litigation, patent, respiratory, Symbicort, Viatris 0 Comment

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing

AstraZeneca breathes sigh of relief as court blocks US Symbicort generic

https://pharmaphorum.com/news/astrazeneca-breathes-sigh-of-relief-as-court-blocks-us-symbicort-generic/

Doctor in the hand shows the scanning of the lung .

News/ News/ R&D

Boost for Verona Pharma after trial win with inhaled COPD drug

Richard Staines COPD, ensifenitrine, R&D, respiratory 0 Comment

UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after

Boost for Verona Pharma after trial win with inhaled COPD drug

https://pharmaphorum.com/news/verona-pharma-scores-trial-win-with-inhaled-copd-drug/

Digital/ Video/ Views & Analysis/ Views and analysis

Health Innovators: David Van Sickle on digital innovation in respiratory medicine

Catherine Longworth asthma, COPD, digital health, health innovators, Propeller Health, respiratory medicine 0 Comment

In the first episode of our Health Innovators series, Paul Tunnah speaks to David Van Sickle, CEO of

Health Innovators: David Van Sickle on digital innovation in respiratory medicine

https://pharmaphorum.com/views-and-analysis/health-innovators-david-van-sickle-on-digitalising-respiratory-medicine/

News/ News/ R&D

Verona Pharma to trial lung drug ensifentrine for COVID-19

Richard Staines COPD, COVID-19, R&D, respiratory diseases 0 Comment

Verona Pharma is to develop its lung drug ensifentrine for patients with COVID-19, joining the legions of drug

Verona Pharma to trial lung drug ensifentrine for COVID-19

https://pharmaphorum.com/news/verona-pharma-to-develop-lung-drug-for-covid-19/

News/ News/ Sales and Marketing

AZ’s COPD triple therapy approved in the US

Richard Staines AstraZeneca, COPD, fda, GlaxoSmithKline, respiratory diseases 0 Comment

AstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the

AZ’s COPD triple therapy approved in the US

https://pharmaphorum.com/news/azs-copd-triple-therapy-approved-in-the-us/

Trending

COPD

Login